tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SpringWorks expects CHMP of EMA will adopt MAA opinion on nirogacestat in Q2

SpringWorks Therapeutics (SWTX) announced that the Company anticipates the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, will adopt an opinion on the marketing authorization application, MAA, for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1